BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7484817)

  • 1. Interactions and drug-metabolizing enzymes.
    Ciummo PE; Katz NL
    Am Pharm; 1995 Sep; NS35(9):41-51; quiz 51-3. PubMed ID: 7484817
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)-induced ventricular arrhythmias.
    Wynn RL
    Gen Dent; 1993; 41(1):27-9. PubMed ID: 7489857
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes.
    Hey JA; del Prado M; Kreutner W; Egan RW
    Arzneimittelforschung; 1996 Feb; 46(2):159-63. PubMed ID: 8720305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview: pharmacokinetic drug-drug interactions.
    Li AP; Jurima-Romet M
    Adv Pharmacol; 1997; 43():1-6. PubMed ID: 9342170
    [No Abstract]   [Full Text] [Related]  

  • 5. Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm.
    Carlson AM; Morris LS
    J Am Pharm Assoc (Wash); 1996 Apr; NS36(4):263-9. PubMed ID: 8919602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin.
    Biglin KE; Faraon MS; Constance TD; Lieh-Lai M
    Ann Pharmacother; 1994 Feb; 28(2):282. PubMed ID: 8173153
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular toxicity of antihistamines.
    Smith SJ
    Otolaryngol Head Neck Surg; 1994 Sep; 111(3 Pt 2):348-54. PubMed ID: 7916150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probable terfenadine-fluoxetine-associated cardiac toxicity.
    Marchiando RJ; Cook MD; Jue SG
    Ann Pharmacother; 1995 Sep; 29(9):937-8. PubMed ID: 8547749
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug interactions: Part I.
    Gibaldi M
    Ann Pharmacother; 1992 May; 26(5):709-13. PubMed ID: 1591436
    [No Abstract]   [Full Text] [Related]  

  • 11. Torsades de pointes after terfenadine-itraconazole interaction.
    Pohjola-Sintonen S; Viitasalo M; Toivonene L; Neuvonen P
    BMJ; 1993 Jan; 306(6871):186. PubMed ID: 8382980
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment with terfenadine and ketoconazole or itraconazole can cause torsades de pointes ventricular tachycardia].
    Pohjola-Sintonen S
    Duodecim; 1993; 109(2):164-6. PubMed ID: 8013320
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug interactions with macrolide antibiotics: specificity of pseudo-suicide inhibition and induction of cytochrome P-450.
    Dansette PM; Delaforge M; Sartori E; Beaune P; Jaouen M; Mansuy D
    Adv Exp Med Biol; 1986; 197():155-62. PubMed ID: 3490132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torsades de Pointes after treatment with terfenadine and ketoconazole.
    Zimmermann M; Duruz H; Guinand O; Broccard O; Levy P; Lacatis D; Bloch A
    Eur Heart J; 1992 Jul; 13(7):1002-3. PubMed ID: 1644069
    [No Abstract]   [Full Text] [Related]  

  • 15. [Torsades de pointes caused by the association of terfenadine and erythromycin].
    Gully C; Riem R
    Ann Med Interne (Paris); 1994; 145(4):257-8. PubMed ID: 8092653
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience.
    Rodrigues AD; Wong SL
    Adv Pharmacol; 1997; 43():65-101. PubMed ID: 9342173
    [No Abstract]   [Full Text] [Related]  

  • 17. Torsades de pointes induced by erythromycin and terfenadine.
    Paris DG; Parente TF; Bruschetta HR; Guzman E; Niarchos AP
    Am J Emerg Med; 1994 Nov; 12(6):636-8. PubMed ID: 7945604
    [No Abstract]   [Full Text] [Related]  

  • 18. Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine-related drug interaction.
    Ishizaki T
    J Toxicol Sci; 1996 Dec; 21(5):301-3. PubMed ID: 9035041
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of human cytochrome P450 enzymes.
    Guengerich FP
    FASEB J; 1992 Jan; 6(2):745-8. PubMed ID: 1537465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsades de pointes occurring in association with terfenadine use.
    Monahan BP; Ferguson CL; Killeavy ES; Lloyd BK; Troy J; Cantilena LR
    JAMA; 1990 Dec; 264(21):2788-90. PubMed ID: 1977935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.